{
  "first_published_at": "2014-10-14", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON462304", 
  "title": "Basiliximab indicated for renal transplantation only; efficacy and safety not shown in heart transplantation ", 
  "tags": "{\"parsed_therapeutic\": [\"immunosuppression-transplantation\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Immunosuppression and transplantation\"]}", 
  "_document_number": 8, 
  "label": "Reminder", 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "immunosuppression-transplantation"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Basiliximab indicated for renal transplantation only; efficacy and safety not shown in heart transplantation </h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--In clinical trials, serious cardiac side effects were observed more frequently with basiliximab than with other induction agents.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Basiliximab (Simulect) is indicated for preventing acute organ rejection only for allogeneic renal transplantation in patients receiving organ transplantation for the first time.</p>\n\n<p>A European regulatory review investigated the safety and efficacy of basiliximab for off-label use in heart transplantation. This review was triggered by three unexplained deaths in Sweden in patients who received basiliximab for heart transplantation. All three patients had signs and symptoms of thromboembolic events and potential cardiac disorders.</p>\n\n<p>The review found no adequately powered randomised studies of basiliximab in heart transplantation. The clinical trials that have been done in heart transplantation did not prove basiliximab to be effective. Furthermore, serious cardiac side effects such as cardiac arrest, atrial flutter, and palpitations were observed more frequently with basiliximab than with other induction agents. Therefore a new warning has been included in the basiliximab product information regarding the lack of proven safety and efficacy in heart transplantation (see link below).</p>\n\n<h3><strong>Call for reporting</strong></h3>\n\n<p>Please continue to report all suspected adverse drug reactions to us on a Yellow Card (<a target=\"_blank\" href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>).</p>\n\n<h3><strong>Further information</strong></h3>\n\n<p><a href=\"/Opendocuments/OpenPDFdocuments/CON464230\">Letter sent to healthcare professionals in September 2014</a></p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/12889\">Basiliximab summary of product characteristics</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 3, October 2014: S1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n\t\t\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Basiliximab (Simulect) is indicated for preventing acute organ rejection only for allogeneic renal transplantation in patients receiving organ transplantation for the first time.</p>\n\n<p>A European regulatory review investigated the safety and efficacy of basiliximab for off-label use in heart transplantation. This review was triggered by three unexplained deaths in Sweden in patients who received basiliximab for heart transplantation. All three patients had signs and symptoms of thromboembolic events and potential cardiac disorders.</p>\n\n<p>The review found no adequately powered randomised studies of basiliximab in heart transplantation. The clinical trials that have been done in heart transplantation did not prove basiliximab to be effective. Furthermore, serious cardiac side effects such as cardiac arrest, atrial flutter, and palpitations were observed more frequently with basiliximab than with other induction agents. Therefore a new warning has been included in the basiliximab product information regarding the lack of proven safety and efficacy in heart transplantation (see link below).</p>\n\n<h3><strong>Call for reporting</strong></h3>\n\n<p>Please continue to report all suspected adverse drug reactions to us on a Yellow Card (<a target=\"_blank\" href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>).</p>\n\n<h3><strong>Further information</strong></h3>\n\n<p><a href=\"http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con464230.pdf\" target='new\"\"'>Letter sent to healthcare professionals in September 2014<img src=\"http://www.mhra.gov.uk/home/images/MHRALook/img/icon/acroread.gif\" alt=\"PDF file (opens in new window)\" width=\"16\" height=\"16\" title=\"PDF file (opens in new window)\" border=\"0\"></a> (275Kb)</p>\n\n<p><a target=\"_blank\" href=\"https://www.medicines.org.uk/emc/medicine/12889\">Basiliximab summary of product characteristics</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 8 issue 3, October 2014: S1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-10-01", 
  "date_last_modified": "2014-10-14", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Letter sent to healthcare professionals in September 2014", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con464230.pdf", 
      "filename": "downloads/f39d650e7c2409e475ed475aa1f4b087c79b0067/con464230.pdf", 
      "original_filename": "con464230.pdf"
    }
  ], 
  "_item_id": 8, 
  "summary": "", 
  "body": "Article date: October 2014\n\nBasiliximab (Simulect) is indicated for preventing acute organ rejection only for allogeneic renal transplantation in patients receiving organ transplantation for the first time.\n\nA European regulatory review investigated the safety and efficacy of basiliximab for off-label use in heart transplantation. This review was triggered by three unexplained deaths in Sweden in patients who received basiliximab for heart transplantation. All three patients had signs and symptoms of thromboembolic events and potential cardiac disorders.\n\nThe review found no adequately powered randomised studies of basiliximab in heart transplantation. The clinical trials that have been done in heart transplantation did not prove basiliximab to be effective. Furthermore, serious cardiac side effects such as cardiac arrest, atrial flutter, and palpitations were observed more frequently with basiliximab than with other induction agents. Therefore a new warning has been included in the basiliximab product information regarding the lack of proven safety and efficacy in heart transplantation (see link below).\n\n### Call for reporting\n\nPlease continue to report all suspected adverse drug reactions to us on a Yellow Card ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)).\n\n### Further information\n\n[ASSET_TAG](#ASSET0) (275Kb)\n\n[Basiliximab summary of product characteristics](https://www.medicines.org.uk/emc/medicine/12889)\n\nArticle citation: Drug Safety Update volume 8 issue 3, October 2014: S1\n"
}